USANA Health Sciences, Inc. (NYSE:USNA) Director Gilbert A. Fuller sold 282 shares of the firm’s stock in a transaction dated Monday, November 5th. The shares were sold at an average price of $113.54, for a total transaction of $32,018.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of USANA Health Sciences stock opened at $119.56 on Friday. The stock has a market capitalization of $2.89 billion, a P/E ratio of 29.45 and a beta of 0.80. USANA Health Sciences, Inc. has a twelve month low of $64.70 and a twelve month high of $137.95.
USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Tuesday, October 23rd. The company reported $1.24 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.10 by $0.14. The firm had revenue of $296.80 million for the quarter, compared to analyst estimates of $289.54 million. USANA Health Sciences had a net margin of 7.57% and a return on equity of 30.37%. USANA Health Sciences’s quarterly revenue was up 13.4% compared to the same quarter last year. During the same period last year, the company posted $1.03 EPS. As a group, equities analysts anticipate that USANA Health Sciences, Inc. will post 4.9 earnings per share for the current fiscal year.
A number of institutional investors have recently modified their holdings of the stock. NEXT Financial Group Inc purchased a new position in USANA Health Sciences in the 3rd quarter worth approximately $121,000. Harvest Fund Management Co. Ltd lifted its stake in USANA Health Sciences by 418.6% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 1,224 shares of the company’s stock worth $148,000 after purchasing an additional 988 shares in the last quarter. CAPROCK Group Inc. purchased a new position in USANA Health Sciences in the 2nd quarter worth approximately $214,000. Amalgamated Bank purchased a new position in USANA Health Sciences in the 2nd quarter worth approximately $223,000. Finally, RNC Capital Management LLC purchased a new position in USANA Health Sciences in the 2nd quarter worth approximately $231,000. 52.20% of the stock is currently owned by hedge funds and other institutional investors.
A number of research analysts recently weighed in on the stock. Sidoti raised shares of USANA Health Sciences from a “neutral” rating to a “buy” rating in a research note on Thursday, October 25th. Pivotal Research raised shares of USANA Health Sciences from a “hold” rating to a “buy” rating and set a $135.00 price target on the stock in a research note on Wednesday, October 24th. Finally, ValuEngine lowered shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Thursday.
COPYRIGHT VIOLATION NOTICE: “Gilbert A. Fuller Sells 282 Shares of USANA Health Sciences, Inc. (USNA) Stock” was reported by WKRB News and is owned by of WKRB News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.wkrb13.com/2018/11/10/gilbert-a-fuller-sells-282-shares-of-usana-health-sciences-inc-usna-stock.html.
About USANA Health Sciences
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.
Recommended Story: What are the most popular ETFs
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.